Our Team

Dr. Dalvir Gill has more than three decades of expertise in drug development across multiple therapeutic areas. He has held executive leadership position in both the pharmaceutical and the pharmaceutical services industries. Most recently he was the founding CEO and member of the Board of Directors of TransCelerate BioPharma and led the organization for 10 years. Dalvir took TransCelerate from inception to becoming the most successful biopharmaceutical collaborative in history with 20 of the largest biopharmaceutical companies funding it. Under his leadership TransCelerate generated dozens of transformative solutions that are publicly available and in everyday use in the global drug development ecosystem. Before he was recruited to start TransCelerate, Dalvir was the Global President of Drug Development at InVentiv Health which was one of the largest service providers to the biopharmaceutical industry. In that role he was responsible for a global business spanning nearly 40 countries and was responsible for all operational and business departments. Prior to that Dalvir spent 10 years at Rhone Poulenc Rorer (now Sanofi) and was part of the oncology leadership team that developed of Taxotere. He co-authored the clinical development plan for the regulatory submission of Taxotere in Platinum Refractory NSCLC that used an innovative and first ever use of a Best Supportive Care control arm in a pivotal oncology study. Taxotere went on to become one of the most successful oncology drugs in history and has been used to treat millions of cancer patients around the world. Dalvir has served on multiple boards and Executive Committees. He was member of the Executive Committee Member of the Clinical Trials Transformation Initiative, a public-private partnership co-founded by FDA and Duke University to increase the quality and efficiency of clinical trials. He also served as an Executive Committee member of the Society of Clinical Research Sites. Dalvir has a PhD in Pathobiology from the Royal Free Hospital School of Medicine, University of London. He also attended the Stockholm School of Economics to study the Health Economics of Pharmaceuticals. Dalvir has presented his research at numerous conferences and has authored more than 30 scientific publications. He is an elected fellow of the Royal Society of Medicine.